Scarica l'app Stockscreener
21.14
1.72%
-0.37
Dopo l'orario di chiusura:
21.14
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CSTL Giù?
Forum
Previsione
Precedente Chiudi:
$21.51
Aprire:
$21.41
Volume 24 ore:
635.22K
Relative Volume:
1.60
Capitalizzazione di mercato:
$573.73M
Reddito:
$219.79M
Utile/perdita netta:
$-57.47M
Rapporto P/E:
-9.8326
EPS:
-2.15
Flusso di cassa netto:
$-19.25M
1 W Prestazione:
+6.28%
1M Prestazione:
+3.02%
6M Prestazione:
-33.67%
1 anno Prestazione:
+9.48%
Intervallo 1D:
$21.12
$21.79
Intervallo di 1 settimana:
$19.75
$21.81
Portata 52W:
$16.96
$35.84
Castle Biosciences Inc Stock (CSTL) Company Profile
Nome
Castle Biosciences Inc
Settore
Industria
Telefono
866-788-9007
Indirizzo
505 S FRIENDSWOOD DRIVE, FRIENDSWOOD, TX
Confronta CSTL con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CSTL
Castle Biosciences Inc
|
21.14 | 573.73M | 219.79M | -57.47M | -19.25M | -2.15 |
|
TMO
Thermo Fisher Scientific Inc
|
421.85 | 169.62B | 42.88B | 6.34B | 7.27B | 16.53 |
|
DHR
Danaher Corp
|
184.96 | 138.06B | 23.88B | 3.90B | 5.30B | 5.28 |
|
IDXX
Idexx Laboratories Inc
|
406.65 | 32.79B | 3.90B | 887.87M | 798.08M | 10.67 |
|
A
Agilent Technologies Inc
|
100.26 | 29.99B | 6.53B | 1.26B | 1.31B | 4.35 |
|
IQV
Iqvia Holdings Inc
|
141.22 | 26.61B | 15.41B | 1.37B | 2.11B | 7.50 |
Castle Biosciences Inc Stock (CSTL) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2023-12-14 | Iniziato | Guggenheim | Buy |
| 2023-01-05 | Iniziato | Scotiabank | Sector Outperform |
| 2022-01-07 | Iniziato | Stephens | Overweight |
| 2021-04-30 | Iniziato | Lake Street | Buy |
| 2020-11-10 | Iniziato | KeyBanc Capital Markets | Overweight |
| 2019-12-27 | Reiterato | Canaccord Genuity | Buy |
| 2019-08-19 | Iniziato | BTIG Research | Buy |
| 2019-08-19 | Iniziato | Canaccord Genuity | Buy |
| 2019-08-19 | Iniziato | Robert W. Baird | Outperform |
| 2019-08-19 | Iniziato | SVB Leerink | Outperform |
Mostra tutto
Castle Biosciences Inc Borsa (CSTL) Ultime notizie
Castle Biosciences, Inc. (NASDAQ:CSTL) Stake Raised by Geode Capital Management LLC - Defense World
When Should You Buy Castle Biosciences, Inc. (NASDAQ:CSTL)? - simplywall.st
Castle Biosciences: Steady Revenue Stream, But Medicare Reimbursement Loss A Concern - Seeking Alpha
Castle Biosciences to Release First Quarter 2025 Financial Resul - GuruFocus
Castle Biosciences to Release First Quarter 2025 Financial Results and Host Conference Call on Monday, May 5, 2025 - GlobeNewswire
Castle Biosciences Sets Q1 Earnings Date: Key Financial Updates Coming May 5 - Stock Titan
Castle Biosciences, Inc. (NASDAQ:CSTL) Shares Acquired by Franklin Resources Inc. - Defense World
28,903 Shares in Castle Biosciences, Inc. (NASDAQ:CSTL) Acquired by Arrowstreet Capital Limited Partnership - Defense World
Vanguard Group Inc. Has $48.84 Million Stake in Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World
Corebridge Financial Inc. Has $343,000 Stock Holdings in Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World
Castle Biosciences CEO Derek Maetzold sells $113,931 in stock By Investing.com - Investing.com Canada
KLP Kapitalforvaltning AS Buys New Position in Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World
Castle Biosciences CEO Derek Maetzold sells $113,931 in stock - Investing.com
SEC Form DEF 14A filed by Castle Biosciences Inc. - Quantisnow
American Century Companies Inc. Has $1.84 Million Holdings in Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World
Castle Biosciences backs esophageal cancer awareness By Investing.com - Investing.com South Africa
Castle Biosciences backs esophageal cancer awareness - Investing.com
Castle Biosciences Strengthens Commitment to Esophageal Cancer Awareness Through Collaborative Partnerships - GlobeNewswire
Game-Changing Esophageal Cancer Detection: Castle Bio Partners With Top Medical Networks - Stock Titan
Sei Investments Co. Boosts Position in Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World
Castle Biosciences Honored with a Top Workplaces USA Award for Fourth Consecutive Year - GlobeNewswire
Castle Biosciences Ranks #30 Among Best U.S. Workplaces: 85% Employee Engagement Score - Stock Titan
Castle Biosciences, Inc. (NASDAQ:CSTL) Given Average Recommendation of “Buy” by Brokerages - Defense World
Publication of Data from Prospective, Multicenter Study Demonstrates Positive Survival Outcomes in Patients with Low-Risk Melanoma Who Avoided Sentinel Lymph Node Biopsy with Information from Castle Biosciences' DecisionDx®-Melanoma Test - The Manila Times
Publication of Data from Prospective, Multicenter Study - GlobeNewswire
Publication of Data from Prospective, Multicenter Study Demonstrates Positive Survival Outcomes in Patients with Low-Risk Melanoma Who Avoided Sentinel Lymph Node Biopsy with Information from Castle Biosciences’ DecisionDx®-Melanoma Test - Yahoo Finance
Breakthrough Melanoma Test Shows 100% Accuracy in Avoiding Unnecessary Cancer Surgeries - Stock Titan
Are Castle Biosciences, Inc.'s (NASDAQ:CSTL) Mixed Financials The Reason For Its Gloomy Performance on The Stock Market? - Yahoo Finance
Teacher Retirement System of Texas Makes New $253,000 Investment in Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World
Castle Biosciences to Present New Data at EADO Supporting the Clinical Value of the DecisionDx®-Melanoma Test in Guiding Risk-Aligned Management of Patients with Melanoma - The Manila Times
Castle Biosciences to Present New Data at EADO Supporting - GlobeNewswire
Breakthrough Melanoma Test Data Reveals Critical Survival Predictions for High-Risk Patients - Stock Titan
Castle Biosciences CEO Derek Maetzold sells $114,573 in stock - Investing.com Australia
Castle Biosciences CEO Derek Maetzold sells $114,573 in stock By Investing.com - Investing.com India
Castle Biosciences' DecisionDx®-SCC Data Earns Top Five Abstract at NCCN 2025, Shows Significantly Enhanced Risk Stratification Beyond Current Staging Within NCCN Risk Groups - The Manila Times
Castle Biosciences' DecisionDx®-SCC Data Earns Top Five - GlobeNewswire
Breakthrough Study: Top-Ranked Cancer Test Doubles Accuracy in Predicting Metastatic Risk - Stock Titan
Castle Biosciences, Inc. (NASDAQ:CSTL) Position Trimmed by Charles Schwab Investment Management Inc. - Defense World
Castle Biosciences, Inc. (NASDAQ:CSTL) Shares Acquired by Bank of New York Mellon Corp - Defense World
Bank of New York Mellon Corp Has $2.25 Million Position in Castle Biosciences, Inc. (NASDAQ:CSTL) - The AM Reporter
CSTL Gears Up to Report Q4 Earnings: Here's What You Should Know - MSN
Beyond the Lab: Artificial Intelligence - Drug Target Review
US Bancorp DE Sells 3,413 Shares of Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World
Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Assetmark Inc. Has $118,000 Stock Position in Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World
Castle Biosciences, Inc. (NASDAQ:CSTL) Given Consensus Recommendation of “Buy” by Analysts - Defense World
Castle Biosciences CEO Derek Maetzold sells $585,673 in stock - Investing.com India
Castle Biosciences CEO Derek Maetzold sells $585,673 in stock By Investing.com - Investing.com UK
New Data to be Presented at the 2025 American Academy of Dermatology (AAD) Annual Meeting Further Strengthens Evidence Supporting the Clinical Value of Castle Biosciences' Dermatology Portfolio - Business Wire
Castle Biosciences Inc to Host Earnings Call - ACCESS Newswire
Solid Earnings Reflect Castle Biosciences' (NASDAQ:CSTL) Strength As A Business - Yahoo Finance
Castle Biosciences Inc Azioni (CSTL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.18%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):